Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Novartis
Boehringer Ingelheim
Baxter
Cantor Fitzgerald
Citi
Johnson and Johnson
McKinsey
Accenture

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,214,865

« Back to Dashboard

Which drugs does patent 6,214,865 protect, and when does it expire?

Patent 6,214,865 protects HALAVEN and is included in one NDA.

This patent has thirty-eight patent family members in twenty-one countries.
Summary for Patent: 6,214,865
Title: Macrocyclic analogs and methods of their use and preparation
Abstract:The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Palme; Monica H. (San Jose, CA), Seletsky; Boris M. (Andover, MA), Towle; Murray J. (Auburn, NH), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonberry, NH)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/334,488
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,214,865

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,214,865

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,097,648 Methods and compositions for use in treating cancer ➤ Subscribe
6,365,759 Intermediate compounds for preparing macrocylcic analogs ➤ Subscribe
6,469,182 Intermediates in the preparation of macrocyclic analogs ➤ Subscribe
8,148,554 Methods and compositions for use in treating cancer ➤ Subscribe
7,470,720 Methods and compositions for use in treating cancer ➤ Subscribe
6,653,341 Methods and compositions for use in treating cancer ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,214,865

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway 2011026 ➤ Subscribe
New Zealand 508597 ➤ Subscribe
Portugal 1087960 ➤ Subscribe
Russian Federation 2245335 ➤ Subscribe
Norway 2011018 ➤ Subscribe
Norway 331183 ➤ Subscribe
Norway 20093217 ➤ Subscribe
Norway 328280 ➤ Subscribe
Norway 20006316 ➤ Subscribe
Luxembourg 91854 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Department of Justice
Deloitte
Queensland Health
McKinsey
Healthtrust
Colorcon
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot